Ensysce Biosciences Inc
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
ENSC$0.33-8.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Federal grants | $305,722 | $789,635 |
| Operating expenses: | ||
| Research and development | 778,904 | 1,796,015 |
| General and administrative | 1,369,782 | 1,554,855 |
| Total operating expenses | 2,148,686 | 3,350,870 |
| Loss from operations | (1,842,964) | (2,561,235) |
| Other income (expense): | ||
| Change in fair value of convertible notes | - | 146,479 |
| Change in fair value of liability classified warrants | 8,955 | 219,028 |
| Interest expense, net | (1,248,065) | (1,497) |
| Other income and expense, net | (34,489) | 5,419 |
| Total other income, net | (1,273,599) | 369,429 |
| Net loss | $(3,116,563) | $(2,191,806) |
| Net loss attributable to noncontrolling interests | (74) | (3,941) |
| Deemed dividend related to warrants down round provision | 290 | 8,309 |
| Net loss attributable to common stockholders | $(3,116,779) | $(2,196,174) |
| Net loss per basic and diluted share: | ||
| Net loss per share attributable to common stockholders, basic and diluted | $(0.55) | $(2.08) |
| Weighted average common shares outstanding, basic and diluted | 5,694,466 | 1,054,202 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.